Package Leaflet: Information for the User
Inovelon100mgfilm-coated tablets
Inovelon200mgfilm-coated tablets
Inovelon400mgfilm-coated tablets
Rufinamide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information:
Inovelon contains a medicine called rufinamide. It belongs to a group of medicines called antiepileptics, which are used to treat epilepsy (a condition that causes seizures or fits).
Inovelon is used with other medicines to treat seizures associated with Lennox-Gastaut syndrome in adults, adolescents, and children from 1 year of age. Lennox-Gastaut syndrome is a severe form of epilepsy where several types of seizures can occur.
Your doctor has prescribed Inovelon to reduce the number of seizures or fits.
Do not take Inovelon:
Warnings and precautions
Tell your doctor or pharmacist:
Please consult your doctor, even if you have had these effects at any time in the past.
Children
Inovelon should not be used in children under 1 year of age because there is not enough information on its use in this age group.
Use of Inovelon with other medicines
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including those obtained without a prescription. If you are taking the following medicines: phenobarbital, fosphenytoin, phenytoin or primidone, you may need to be closely monitored for two weeks at the start or end of treatment with rufinamide, or after any significant change in the dose. You may need to have the dose of the other medicines changed as they may be less effective when given with rufinamide.
Antiepileptics and Inovelon
If your doctor prescribes or recommends additional treatment for epilepsy (e.g. valproate), you should tell them that you are taking Inovelon as it may be necessary to adjust the dose.
Taking valproate at the same time as rufinamide in children and adults will result in high levels of rufinamide in the blood. Tell your doctor if you are taking valproate, as they may need to adjust the dose of Inovelon.
Tell your doctor if you are using oral/hormonal contraceptives (i.e. "the pill"). Inovelon may make the pill less effective for preventing pregnancy. Therefore, it is recommended that you use another reliable and effective method of contraception (such as a barrier method, e.g. condoms) while taking Inovelon.
Tell your doctor if you are using blood thinners, such as warfarin. Your doctor may need to adjust the dose.
Tell your doctor if you are using digoxin (a medicine used to treat heart conditions). Your doctor may need to adjust the dose.
Taking Inovelon with food and drink
See section 3 "How to take Inovelon" for recommendations on taking Inovelon with food and drink.
Pregnancy, breastfeeding and fertility
If you are pregnant or think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should only take Inovelon during pregnancy if your doctor advises it.
You are advised not to breastfeed while taking Inovelon as it is not known whether rufinamide passes into breast milk.
If you are a woman of childbearing age, you should use contraceptive methods while taking Inovelon.
Ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines
Inovelon may make you feel dizzy, drowsy and affect your vision, especially at the start of treatment or after a dose increase. If this happens, do not drive or use machines.
Inovelon contains lactose
If your doctor has told you that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Inovelon contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per daily dose, i.e. it is essentially "sodium-free".
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
It may take some time to find the best dose of Inovelon for you. Your doctor will calculate the right dose based on your age, weight, and whether you are taking Inovelon with another medicine called valproate.
Children between 1 and 4 years old
The recommended starting dose is 10 mg per kilogram of body weight per day. It is taken in two equal doses, half in the morning and half in the evening. Your doctor will calculate your dose and may increase it in increments of 10 mg per kilogram of body weight every three days.
The maximum daily dose will depend on whether you are taking valproate or not. The maximum daily dose without valproate is 45 mg per kilogram of body weight per day. The maximum daily dose with valproate is 30 mg per kilogram of body weight per day.
Children aged 4 years or older who weigh less than 30 kg
The recommended starting dose is 200 mg per day. It is taken in two equal doses, half in the morning and half in the evening. Your doctor will calculate your dose and may increase it by 200 mg (5 ml) every three days.
The maximum daily dose will depend on whether you are taking valproate or not. The maximum daily dose without valproate is 1,000 mg per day. The maximum daily dose with valproate is 600 mg per day.
Adults, adolescents, and children who weigh 30 kg or more
The recommended starting dose is 400 mg per day. It is taken in two equal doses, half in the morning and half in the evening. Your doctor will calculate your dose and may increase it by 400 mg on alternate days.
The maximum daily dose will depend on whether you are taking valproate or not. The maximum daily dose without valproate should not exceed 3,200 mg, depending on your body weight. The maximum daily dose with valproate should not exceed 2,200 mg, depending on your body weight.
Some patients may respond to lower doses and your doctor may adjust the dose based on your response to treatment.
If you experience side effects, your doctor may increase the dose more slowly.
Inovelon tablets should be taken twice a day with water, in the morning and in the evening. Inovelon should be taken with food. If you have difficulty swallowing, you can crush the tablet, then mix the powder with approximately half a glass of water (100 ml) and drink it immediately. You can also divide the tablets into two equal halves and swallow them with water.
Do not reduce the dose or stop taking this medicine unless your doctor tells you to.
If you take more Inovelon than you should
If you may have taken more Inovelon than you should, tell your doctor or pharmacist immediately, or contact the nearest hospital emergency department, taking the medicine with you.
If you forget to take Inovelon
If you forget to take a dose, continue taking the medicine as usual. Do not take a double dose to make up for the forgotten dose. If you forget to take more than one dose, consult your doctor.
If you stop taking Inovelon
If your doctor tells you to stop treatment, follow their instructions regarding the gradual reduction of Inovelon to reduce the risk of increased seizures.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Inovelon can cause side effects, although not everybody gets them.
The following side effects may be serious:
Skin rash and/or fever. They could be signs of an allergic reaction. If this happens, tell your doctor or go to the hospital immediately.
Change in the types of seizures you have/more frequent seizures that last a long time (called status epilepticus). Tell your doctor immediately.
A small number of people taking antiepileptics like Inovelon have had thoughts of harming themselves or committing suicide. If you have these thoughts at any time, contact your doctor immediately(see section 2).
You may experience the following side effects with this medicine. Tell your doctor if you experience any of the following:
The very common side effects (affecting more than 1 in 10 people) of Inovelon are:
Dizziness, headache, nausea, vomiting, drowsiness, fatigue.
The common side effects (affecting more than 1 in 100 people) of Inovelon are:
Nervous system problems including: difficulty walking, abnormal movements, seizures/convulsions, unusual eye movements, blurred vision, tremors.
Stomach problems including: stomach pain, constipation, indigestion, soft stools (diarrhea), loss or change in appetite, weight loss.
Infections: ear infection, flu, nasal congestion, lung infection
Additionally, patients have experienced: anxiety, insomnia, nosebleeds, acne, skin rash, back pain, infrequent menstruation, bruising, head injuries (as a result of an accidental injury during an epileptic seizure).
The uncommon side effects (affecting less than 1 in 100 people but more than 1 in 1,000 people) of Inovelon are:
Allergic reactions and increased liver function tests (increased liver enzymes).
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Vigilance System for Human Use www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and carton. The expiry date is the last day of the month stated.
Do not store above 30°C.
Do not use this medicine if you notice that the appearance of the medicine has changed.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Inovelon
Each 100 mg film-coated tablet contains 100 mg of rufinamide.
Each 200 mg film-coated tablet contains 200 mg of rufinamide.
Each 400 mg film-coated tablet contains 400 mg of rufinamide.
Appearance of Inovelon and pack contents
They are available in packs of 10, 30, 50, 60, and 100 film-coated tablets.
They are available in packs of 10, 30, 50, 60, and 100 film-coated tablets.
They are available in packs of 10, 30, 50, 60, 100, and 200 film-coated tablets.
Marketing authorisation holder and manufacturer
Marketing authorisation holder:
Eisai GmbH
Edmund-Rumpler-Straße 3
60549 Frankfurt am Main
Germany
e-mail: medinfo_de@eisai.net
Manufacturer:
Eisai GmbH
Edmund-Rumpler-Straße 3
60549 Frankfurt am Main
Germany
You can obtain further information on this medicine from the local representative of the marketing authorisation holder:
Belgium Eisai SA/NV Tel: +32 (0)800 158 58 | Lithuania Eisai GmbH Tel: + 49 (0) 69 66 58 50 |
Bulgaria Eisai GmbH Tel: + 49 (0) 69 66 58 50 | Luxembourg Eisai SA/NV Tel: +32 (0)800 158 58 (Belgium) |
Czech Republic Eisai GesmbH organisational unit Tel: + 420 242 485 839 | Hungary Eisai GmbH Tel: + 49 (0) 69 66 58 50 |
Denmark Eisai AB Tel: + 46 (0) 8 501 01 600 (Sweden) | Malta Associated Drug Co. Ltd Tel: + 356 2277 8000 |
Germany Eisai GmbH Tel: + 49 (0) 69 66 58 50 | Netherlands Eisai B.V. Tel: + 31 (0) 900 575 3340 |
Estonia Eisai GmbH Tel: + 49 (0) 69 66 58 50 (Germany) | Norway Eisai AB Tel: + 46 (0) 8 501 01 600 (Sweden) |
Greece Arriani Pharmaceutical S.A. Tel: + 30 210 668 3000 | Austria Eisai GesmbH Tel: + 43 (0) 1 535 1980-0 |
Spain Eisai Farmacéutica, S.A. Tel: + (34) 91 455 94 55 | Poland Eisai GmbH Tel: + 49 (0) 69 66 58 50 (Germany) |
France Eisai SAS Tel: + (33) 1 47 67 00 05 | Portugal Eisai Farmacêutica, Unipessoal Lda Tel: + 351 214 875 540 |
Croatia Eisai GmbH Tel: + 49 (0) 69 66 58 50 | Romania Eisai GmbH Tel: + 49 (0) 69 66 58 50 (Germany) |
Ireland Eisai GmbH Tel: + 49 (0) 69 66 58 50 | Slovenia Eisai GmbH Tel: + 49 (0) 69 66 58 50 (Germany) |
Iceland Eisai AB Tel: + 46 (0)8 501 01 600 (Sweden) | Slovak Republic Eisai GesmbH organisational unit Tel: + 420 242 485 839 (Czech Republic) |
Italy Eisai S.r.l. Tel: + 39 02 5181401 | Finland Eisai AB Tel: + 46 (0) 8 501 01 600 (Sweden) |
Cyprus Arriani Pharmaceuticals S.A. Tel: + 30 210 668 3000 (Greece) | Sweden Eisai AB Tel: + 46 (0) 8 501 01 600 |
Latvia Eisai GmbH Tel: + 49 (0) 69 66 58 50 (Germany) | United Kingdom (Northern Ireland) Eisai GmbH Tel: + 49 (0) 69 66 58 50 (Germany) |
Date of last revision of this leaflet:
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu